Evofem Biosciences, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
OID
Evofem Biosciences, a women's health company, is seeking stockholder approval for a reverse stock split to meet Nasdaq listing standards and enable a critical capital raise, following a year of mixed financial performance and a terminated merger.
OID
Evofem Biosciences announced a new date for its Special Meeting of Stockholders and clarified the availability of dissenters' rights for shareholders.
OID
Evofem Biosciences anticipates stockholder approval of its merger with Aditxt at a special meeting on September 26, 2025.
OID
Evofem Biosciences announced a special meeting of stockholders to vote on a merger agreement with Aditxt, Inc., with the transaction expected to close in the second half of 2025.
OID
Evofem Biosciences, Inc. has increased its authorized Series E-1 Preferred Stock to 10,000 shares, primarily to facilitate dividend payments in kind, following approval by preferred stockholders and the Board.